According to a press release issued by Achillion Pharmaceuticals, the US Food and Drug Administration has granted fast-track designation to the company's experimental hepatitis C (HCV) drug.
ACH-1625, a once-daily protease inhibitor, is in the midst of a Phase IIa trial for the treatment of genotype 1 treatment-naive hepatitis C virus or HCV. The company is also collecting data for HCV genotype 3 treatment, and initial proof-of-concept data for ACH-2684.
Achillion further is intent on exploring ACH-1625 in combination with other oral antiviral agents for treating all HCV genotypes.
In the second segment of this ongoing Phase 2a trial, three doses of once-daily ACH-1625 in combination with pegylated interferon alfa-2a and ribavirin (P/R) were dosed over 12 weeks of therapy in patients with treatment-naive HCV genotype 1.
Because the hepatitis C virus is linked to several cancers, including liver cancer, some subtypes of lymphoma, and multiple myeloma, an effective treatment for hepatitis C could contribute to a lower incidence of these diseases.
Sources: Achillion, Nasdaq.com
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
